Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA, SGLT2i Jul 26 | 2019Sanofi Terminates Partnership with Lexicon for Sotagliflozin DevelopmentPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin Jul 26 | 2019Biocon CY Q2 '19 (FY Q1 '20) Earnings UpdatePurchase Blast$599
Posted in: Glucagon Jul 26 | 2019FENIX Analysis: Baqsimi, Lilly’s Novel Nasal Glucagon Hypo Rescue ProductPurchase Blast$599
Posted in: DPP-IVi, GLP-1RA, SGLT2i Jul 25 | 2019DECLARE Approval Timeline Moved Up; AZ Q2 '19 Earnings UpdatePurchase Blast$599
Posted in: Glucose Monitoring, Other Jul 23 | 2019Is Glooko Eying an IPO? New Partnership with Pack Health for Patient CoachingPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Jul 23 | 2019Medtronic Files CGM for Non-Adjunctive ClaimPurchase Blast$599
Posted in: Bolus Insulin, DPP-IVi, GLP-1RA, Glucagon Jul 22 | 2019REWIND CHMP Decision This Week; CHMP Agenda HighlightsPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin Jul 12 | 2019New Legislation to Impact Generic Insulin ApprovalsPurchase Blast$599
Posted in: Basal Insulin Jul 08 | 2019Biocon Malaysian Facility Receives Additional 483 Observations From FDAPurchase Blast$599
Posted in: Dual/triple agonist Jul 08 | 2019Janssen-Hanmi Ends Ph2 Dual Agonist; Sanofi Efpeg Deal RestructuredPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Jul 03 | 2019Connected Care: Sanofi/Biocorp Exclusive Data PartnershipPurchase Blast$599
Posted in: Insulin Delivery Jul 01 | 2019Beta Bionics Raises $63M in Series B2 FinancingPurchase Blast